Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

(2012) R Elsby et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

(2012) J Honkalammi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

(2012) A Rostami-Hodjegan   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Perspective on Efflux Transport Proteins in the Liver

(2012) K Köck et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evidence-based approach to assess passive diffusion and carrier-mediated drug transport

(2012) Li Di et al.   DRUG DISCOVERY TODAY

Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins

(2012) Pradeep Sharma et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

(2012) Yurong Lai et al.   Expert Opinion on Drug Metabolism & Toxicology

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

(2012) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

PET Imaging-Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me

(2012) T. Takashima et al.   JOURNAL OF NUCLEAR MEDICINE

pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery

(2012) Manthena V. Varma et al.   MOLECULAR PHARMACEUTICS

Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3

(2012) Keiji Shimizu et al.   NUCLEAR MEDICINE AND BIOLOGY

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

(2012) Manthena V. S. Varma et al.   PHARMACEUTICAL RESEARCH

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

(2011) Malcolm Rowland et al.   Annual Review of Pharmacology and Toxicology

Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use

(2011) Bharat Damle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

(2011) Alicia J. Allred et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment

(2011) Lan-Xiang Wu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism

(2011) Jianghong Fan et al.   CURRENT DRUG METABOLISM

Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

(2011) J. Honkalammi et al.   DRUG METABOLISM AND DISPOSITION

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

(2011) Y. Yabe et al.   DRUG METABOLISM AND DISPOSITION

Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes

(2011) N. Kotani et al.   DRUG METABOLISM AND DISPOSITION

Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin

(2011) Divya Samineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

(2011) Maria Karlgren et al.   PHARMACEUTICAL RESEARCH

Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat

(2011) Ken-ichi Umehara et al.   PHARMACEUTICAL RESEARCH

Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity

(2011) Ute I. Schwarz et al.   Pharmacogenetics and Genomics

Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

(2011) M. Niemi et al.   PHARMACOLOGICAL REVIEWS

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

(2011) Katherine S. Fenner et al.   XENOBIOTICA

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models

(2010) Eleanor J. Guest et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes

(2010) E. Kimoto et al.   DRUG METABOLISM AND DISPOSITION

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

(2010) Christina Fahrmayr et al.   DRUG METABOLISM REVIEWS

Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans

(2010) Takao Watanabe et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Improved Extrapolation of Hepatobiliary Clearance fromin VitroSandwich Cultured Rat Hepatocytes through Absolute Quantification of Hepatobiliary Transporters

(2010) Na Li et al.   MOLECULAR PHARMACEUTICS

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation

(2010) C. D. Klaassen et al.   PHARMACOLOGICAL REVIEWS

Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine

(2009) Michael B. Bolger et al.   AAPS Journal

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

(2009) P. A. Pham et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects

(2009) Sheng Deng et al.   CLINICAL THERAPEUTICS

Saturation of Multidrug-Resistant Protein 2 (Mrp2/Abcc2)-Mediated Hepatobiliary Secretion: Nonlinear Pharmacokinetics of a Heterocyclic Compound in Rats after Intravenous Bolus Administration

(2009) Y. Hu et al.   DRUG METABOLISM AND DISPOSITION

Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments

(2009) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

(2009) Anthony J Busti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data

(2009) Agnès Poirier et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Impact of Hepatic Uptake Transporters on Pharmacokinetics and Drug−Drug Interactions: Use of Assays and Models for Decision Making in the Pharmaceutical Industry

(2009) Mathew G. Soars et al.   MOLECULAR PHARMACEUTICS

Hepatic Nuclear Factor 1  Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin

(2008) Y.-J. He et al.   DRUG METABOLISM AND DISPOSITION

Rate-Limiting Steps in Hepatic Drug Clearance: Comparison of Hepatocellular Uptake and Metabolism with Microsomal Metabolism of Saquinavir, Nelfinavir, and Ritonavir

(2008) A. J. Parker et al.   DRUG METABOLISM AND DISPOSITION

A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

(2008) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human

(2008) Meng Li et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

(2008) T. Watanabe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

(2008) Motohiro Kato et al.   PHARMACEUTICAL RESEARCH